Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2018-11-30
2019-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators propose a more cost-effective, resource-savvy solution in the form of REmotely SuPervised ExerCise Training (RESPECT). This allows the patient to exercise in the convenience of their own home, at a time of their choosing but still be supervised via fitness tracker technology and an online fitness platform. This randomised controlled trial will attempt to prove its' effectiveness in increasing claudication distance, improving functional ability, decreasing cardiovascular risk and improving quality of life whilst being more cost-effective than the currently recognised national first line treatment. This trial has the potential to revolutionise the management of patients with peripheral arterial disease.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Digital Support for Supervised Exercise Therapy in Peripheral Arterial Disease
NCT04947228
Community-Based Detection and Treatment of Peripheral Arterial Disease in Hispanics.
NCT01440634
Multifactor Risk Reduction for Optimal Management of PAD
NCT00537225
Lower Extremity Peripheral Arterial Disease and Exercise Ischemia
NCT02041169
Comparative Effectiveness Research Study of Peripheral Arterial Disease (PAD)
NCT01378260
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
REmotely SuPervised Exercise Training
12- week home based exercise programme consisting of bi-weekly, hourly sessions at the time and place of the participant's choosing. They will wear a fitness tracker which will automatically upload their exercise data to an online platform which can be monitored by the research team and used to provide additional motivation.
REmotely SuPervised Exercise Training
As described in the Arms section.
Supervised Exercise Training
As per NICE guidance. 12 week, bi-weekly, one hour sessions of supervised exercise training.
Supervised Exercise Training
As described in the Arms section.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
REmotely SuPervised Exercise Training
As described in the Arms section.
Supervised Exercise Training
As described in the Arms section.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Positive Edinburgh questionnaire for intermittent claudication (APPENDIX H)
3. Proven peripheral arterial disease on diagnostic imaging
4. Ankle Brachial Pressure Index (ABPI) \<0.9
5. Fontaine Classification (APPENDIX I) of PAD Stage II
6. Conservative management plan agreed for by Consultant Vascular Surgeon.
Exclusion Criteria
2. Asymptomatic peripheral arterial disease
3. Ambulation limited by co-morbid condition other than claudication:
Severe coronary artery disease, angina pectoris, chronic lung disease, neurological disorder, arthritis, amputation
4. Contraindication to exercise training (AHA guidelines):71 acute MI (within 1 week), unstable angina, uncontrolled cardiac arrhythmias causing symptoms or haemodynamic compromise, active endocarditis, symptomatic severe aortic stenosis, acute pulmonary embolus, acute noncardiac disorder than may be aggravated by exercise such as infection, thyrotoxicosis, acute myocarditis, known physical disability that would preclude safe and adequate testing, known thrombosis of the lower limb, known left main stem coronary stenosis, moderate stenotic valvular heart disease, pulmonary hypertension, hypertrophic cardiomyopathy, atrio-ventricular block.
5. Psychiatric disorder precluding them from consenting for research and/or exercise training
6. Arterial reconstruction in the previous 12 months or planned within the next 6 months.
7. Recent or upcoming major surgery (within 3 months)
8. Unwilling or unable to attend/perform exercise training
9. Non-atherosclerotic cause of PAD
10. Other significant medical problems which impact on the patient's ability to complete a 12-week exercise programme, which could include:
malignancy, chronic renal disease, chronic liver disease or anaemia, active substance abuse, dementia
30 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Manchester
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Charles McCollum
Professor of Surgery
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
224506
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.